Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.
Renal Cell Carcinoma
Cabometyx® (cabozantinib) Support Materials
CABOMETYX® is indicated as monotherapy for advanced renal cell carcinoma:
• As first-line treatment of adult patients with intermediate or poor risk
• In adults following prior vascular endothelial growth factor (VEGF)-targeted therapy
CABOMETYX®, in combination with nivolumab, is indicated for the first-line treatment of
advanced renal cell carcinoma in adults.
CABOMETYX® + nivolumab 55.6-month median overall survival in 1st line advanced renal cell carcinoma
Early efficacy with sustained long-term overall survival vs sunitinib: At a median follow-up of 55.6 months (48.1 months minimum), CheckMate 9ER data for CABOMETYX® + nivolumab demonstrate a 10.5-month longer mOS vs sunitinib
CMX-UK-005811 | April 2024
Background to renal cell carcinoma
Pathology of kidney cancer and renal cell carcinoma (RCC). Epidemiology of kidney cancer and RCC. Staging and prognosis of RCC. Treatment of RCC.
CMX-UK-005319 | Oct 23
